Subscribe to Dendreon

The Lead

PROVENGE® to be Commercially Available in Europe

March 3, 2014 8:03 am | News | Comments

Dendreon Corporation today announced that it plans to make PROVENGE ® (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.    

Dendreon Says Provenge Sales Won't Grow in 2013

August 8, 2013 6:28 pm | by The Associated Press | News | Comments


Dendreon said that it no longer expects sales of its prostate cancer therapy...

Dendreon Shares Rise - 4Q Provenge Sales Increase

February 25, 2013 1:18 pm | by The Associated Press | News | Comments

Shares of Dendreon Corp. moved higher Monday after the company said sales of its prostate cancer...

Dendreon Gets Boost From Aetna Coverage Memo

October 1, 2012 4:02 am | News | Comments

WASHINGTON (AP) — Shares of biotech developer Dendreon Corp. rose Friday after health insurer...

View Sample

FREE Email Newsletter

Dendreon Falls on Data for Rival Cancer Drug

June 5, 2012 4:14 am | News | Comments

NEW YORK (AP) — Shares of Dendreon Corp. slumped Monday after Johnson & Johnson reported positive clinical data for a prostate cancer drug that competes with Dendreon's therapy Provenge.  

Dendreon Falls as Analyst Starts Coverage

May 24, 2012 4:07 am | News | Comments

NEW YORK (AP) — Shares of Dendreon Corp. sank Wednesday after a Jefferies & Co. analyst said the company's prostate cancer therapy Provenge will be eclipsed by two newer competitors.  

Dendreon Shares Fall After Disclosure of SEC Probe

May 17, 2012 9:14 am | News | Comments

WASHINGTON (AP) — Shares of biotech drugmaker Dendreon fell today on worries about an investigation into company conduct by financial regulators.  


Dendreon Shares Fall After First Quarter Earnings Report

May 8, 2012 4:29 am | by The Associated Press | News | Comments

Dendreon tumbled more than 12 percent in premarket trading Tuesday after the drug developer reported a loss and what an analyst described as "modest growth" for the company's only marketed product, the prostate cancer treatment Provenge.  

Dendreon Sells Royalty Interest in Victrelis for $125M

December 7, 2011 5:17 am | by Lianne Dane | News | Comments

Dendreon said Tuesday that it sold its royalty interest in Merck & Co.’s hepatitis C drug Victrelis (boceprevir) for $125 million in a move that is expected to strengthen the company’s cash holdings.

Dendreon Will Eliminate 500 Jobs to Slash Spending

September 9, 2011 5:03 am | News | Comments

SEATTLE (AP) — Dendreon Corp. said Thursday that it will eliminate 500 jobs, or more than a quarter of its work force, as it reduces costs to compensate for disappointing sales of its prostate cancer therapy Provenge.

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.